4151.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 06:30):

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide...

Stats
Dagens volum	548 100
Gjennomsnittsvolum	1.31M
Markedsverdi	1 448.86B
EPS	¥0 ( 2024-02-06 )
Neste inntjeningsdato	( ¥28.50 ) 2024-05-07
Last Dividend	¥27.00 ( 2023-06-29 )
Next Dividend	¥0 ( N/A )
P/E	24.99
ATR14	¥1.426 (0.05%)

Volum Korrelasjon

Lang: 0.26 (neutral)

Kort: -0.38 (neutral)

Signal:(55.394) Neutral

Kyowa Kirin Co., Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kyowa Kirin Co., Ltd. Korrelasjon - Valuta/Råvare

-0.69
( moderate negative )

-0.77
( moderate negative )

-0.61
( weak negative )

0.20
( neutral )

-0.44
( neutral )

Kyowa Kirin Co., Ltd. Økonomi

Annual	2023
Omsetning:	¥442.23B
Bruttogevinst:	¥320.62B (72.50 %)
EPS:	¥151.03

FY	2023
Omsetning:	¥442.23B
Bruttogevinst:	¥320.62B (72.50 %)
EPS:	¥151.03

FY	2022
Omsetning:	¥398.37B
Bruttogevinst:	¥311.46B (78.18 %)
EPS:	¥99.68

FY	2021
Omsetning:	¥352.25B
Bruttogevinst:	¥264.40B (75.06 %)
EPS:	¥97.20

Financial Reports:

No articles found.

Kyowa Kirin Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥27.00 (N/A)	¥0 (N/A)	¥27.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Kyowa Kirin Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.39 - Increase likely (47.84%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥2.50	2000-03-28
Last Dividend	¥27.00	2023-06-29
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	49	--
Total Paid Out	¥539.50	--
Avg. Dividend % Per Year	0.00%	--
Score	4.49	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.39
Div. Directional Score	10.00	--

Next Divdend (Est)
(2024-09-23)

¥0 Estimate 3.76 %

Dividend Stability

0.30 Poor

Dividend Score

4.49

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8117.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7458.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6676.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6005.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4709.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3940.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3166.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2139.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9024.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
7915.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.184	1.500	6.33	9.49	[0 - 0.5]
returnOnAssetsTTM	0.0791	1.200	7.36	8.83	[0 - 0.3]
returnOnEquityTTM	0.101	1.500	9.99	10.00	[0.1 - 1]
payoutRatioTTM	0.358	-1.000	6.42	-6.42	[0 - 1]
currentRatioTTM	4.59	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.93	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.03	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0232	-1.500	9.61	-10.00	[0 - 0.6]
interestCoverageTTM	535.43	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	214.94	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	153.83	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0285	-1.500	9.89	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.742	1.000	0.962	0.962	[0.2 - 0.8]
operatingProfitMarginTTM	0.230	1.000	7.40	7.40	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.84	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.431	0.800	-0.460	-0.368	[0.5 - 2]
Total Score				12.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.66	1.000	8.32	0	[1 - 100]
returnOnEquityTTM	0.101	2.50	9.99	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	153.83	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.10	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	214.94	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.358	1.500	6.42	-6.42	[0 - 1]
pegRatioTTM	7.65	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.261	1.000	5.97	0	[0.1 - 0.5]
Total Score				7.39

Kyowa Kirin Co., Ltd.

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.